American Heart Journal
Volume 152, Issue 2 , Pages 197-199 , August 2006

The COX-2 inhibitors—An update

  • Curt D. Furberg, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Curt D. Furberg, MD, PhD, Division of Public Health Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1063.

Received 7 April 2006 ,Accepted 3 May 2006.

References 

  1. Cannon CP, Curtis SP, Bolognese JA, et al. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: cardiovascular outcomes with Etoricoxib vs. Diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J [In press].
  2. Decision Memo—Analysis and Recommendations for Agency Action—COX-2 Selective and Non-selective NSAIDs. (Issued 4/6/2005, posted 4/15/05) http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf.
  3. Celebrex label with Black Box warning. http://www.fda.gov/cder/foi/label/2005/020998s018,019lbl.pdf.
  4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–1528
  5. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004;364:675–684
  6. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119:255–266
  7. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99:132–140
  8. Jüni P, Nartey L, Reichenback S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021–2029
  9. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790–804
  10. Piaggio G, Elbourne DR, Altman DG, et al. Reporting of noninferiority and equivalence randomized trials. An extension of the CONSORT statement. JAMA. 2006;295:1152–1160

PII: S0002-8703(06)00470-4

doi: 10.1016/j.ahj.2006.05.022

American Heart Journal
Volume 152, Issue 2 , Pages 197-199 , August 2006

Article Tools